Inside the microscopic world of the mouse hair follicle, Yale Cancer Center researchers have discovered big clues about how stem cells regenerate and die. These findings, reported in the journal Nature, could lead to a better understanding of how the stem cell pool is maintained or altered in tissues throughout the body.

Stem cells are undifferentiated cells that replenish themselves and based on their tissue location can become specialized cells such as blood or skin cells. The hair follicle is an ideal site for exploring stem cell behavior because it has distinct and predictable oscillations in the number and behavior of stem cells, said the study's lead author Kailin R. Mesa, a third-year doctoral student in the lab of Valentina Greco, associate professor of genetics, cell biology and dermatology.

Using live microscopic imaging to track stem cell behavior in the skin of living mice, researchers observed that the stem cell niche, or surrounding area, played a critical role in whether stem cells grow or die.

"Prior to this, it wasn't clear whether stem cell regulation was intrinsic or extrinsic, and now we know it is external in that the niche instructs the stem cells," Mesa said. "In terms of cancer, we can next explore how we might perturb or change the niche in hopes of affecting the growth of cancer stem cells."

Also, researchers were surprised to find that the stem cells within the pool fed on other dying stem cells. This reveals a mechanism for removing dead cells, a process previously observed in mammary glands but never in the skin.

Story Source:

The above story is based on materials provided by Yale Cancer Center. Note: Materials may be edited for content and length.

Read more:
Tiny hair follicle holds big clues about the life and death of stem cells

Inside the microscopic world of the mouse hair follicle, Yale Cancer Center researchers have discovered big clues about how stem cells regenerate and die. These findings, published April 6 in the journal Nature, could lead to a better understanding of how the stem cell pool is maintained or altered in tissues throughout the body.

Stem cells are undifferentiated cells that replenish themselves and, based on their tissue location, can become specialized cells such as blood or skin cells. The hair follicle is an ideal site for exploring stem cell behavior because it has distinct and predictable oscillations in the number and behavior of stem cells, said the studys lead author, Kailin R. Mesa, a third-year doctoral student in the lab of Valentina Greco, associate professor of genetics, cell biology, and dermatology.

Using live microscopic imaging to track stem cell behavior in the skin of living mice, researchers observed that the stem cell niche, or surrounding area, plays a critical role in whether stem cells grow or die.

Prior to this, it wasnt clear whether stem cell regulation was intrinsic or extrinsic, and now we know it is external in that the niche instructs the stem cells, Mesa said. In terms of cancer, we can next explore how we might perturb or change the niche in hopes of affecting the growth of cancer stem cells.

Also, researchers were surprised to find that the stem cells within the pool fed on other dying stem cells. This reveals a mechanism for removing dead cells, a process previously observed in mammary glands but never in the skin.

This study was supported by the Yale Dermatology Spore, National Institutes of Health, American Cancer Society, and New York Stem Cell Foundation.

Citation: Nature

(Photo via Shutterstock)

See the original post here:
Research in the News: Tiny hair follicle offers big clues about the life and death of stem cells

Lifeline Skin Care is stem cell skin care -- the only skin care products in the world based on non-embryonic Human Stem Cell Extracts. These extracts from highly-potent stem cells -- the same stem cells active early in life -- will stimulate your skins own abilities to repair itself and create smooth, beautiful skin. Non-embryonic stem cells means no embryos are created or destroyed.

Stem Cell Extracts Help New Skin Begin Lifeline stem cell skin care uniquely helps your skin build millions of new, young, healthy skin cells. You restore volume and fullness, you fill in lines around the eyes and mouth, and help reverse the damage caused by the sun's UV rays. It's literally "out with the old skin cells, in with the new, young, healthy skin cells."

What Specific Results Does Lifeline Provide? Stem cells are special cells that go to work whenever your skin needs to repair itself. But they become less potent with age. Lifeline Skin Care has discovered a patented, ethical way to take extracts from non-embryonic human stem cells, which then help create millions of new skin cells that rejuvenate skin. An independent clinical study showed the following results:

improve skin hydration by 93% increase skin elasticity by 73% decrease wrinkles appearance by 67% improved skin tone and brightness by 63%

Profits from Lifeline Skin Care are applied to fund stem cell research for curing degenerative diseases like diabetes and Parkinson's Disease, diseases of the liver, and blinding diseases of the eye.

Continued here:
Lifeline Stem Cell Skin Care | Lifeline Skin Care Coupon ...

CIRM funds many projects seeking to better understand heart disease and to translate those discoveries into new therapies.

If you want to learn more about CIRM funding decisions or make a comment directly to our board, join us at a public meeting. You can find agendas for upcoming public meetings on our meetings page.

Find Out More: Stem Cell FAQ | Stem Cell Videos | What We Fund

Find clinical trials: CIRM does not track stem cell clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Heart disease strikes in many forms, but collectively it causes one third of all deaths in the U.S. Many forms of heart disease have a common resultcardiomyopathy. While this is commonly called congestive heart failure (CHF), it is really just the heart becoming less efficient due to any number of causes, but the most common is loss of functioning heart muscle due to the damage caused by a heart attack. An estimated 4.8 million Americans have CHF, with 400,000 new cases diagnosed each year. Half die within five years.

Numerous clinical trials are underway testing a type of stem cell found in borne marrow, called mesenchymal stem cells or MSCs, to see if they are effective in treating the form of CHF that follows a heart attack. While those trials have shown some small improvements in patients the researchers have not found that the MSCs are creating replacement heart muscle. They think the improvements may be due to the MSCs creating new blood vessels that then help make the existing heart muscle healthier, or in other ways strengthening the existing tissue.

Californias stem cell agency has numerous awards looking into heart disease (the full list is below). Most of these involve looking for ways to create stem cells that can replace the damaged heart muscle, restoring the hearts ability to efficiently pump blood around the body. Some researchers are looking to go beyond transplanting cells into the heart and are instead exploring the use of tissue engineering technologies, such as building artificial scaffolds in the lab and loading them with stem cells that, when placed in the heart, may stimulate the recovery of the muscle.

Other CIRM-funded researchers are working in the laboratory, looking at stem cells from heart disease patients to better understand the disease and even using those models to discover and test new drugs to see if they are effective in treating heart disease. Other researchers are trying to make a type of specialized heart cell called a pacemaker cell, which helps keep a proper rhythm to the hearts beat.

We also fund projects that are trying to take promising therapies out of the laboratory and closer to being tested in people. These Disease Team Awards encourage the creation of teams that have both the scientific knowledge and business skills needed to produce therapies that can get approval from the Food and Drug Administration (FDA) to be tested in people. In some cases, these awards also fund the early phase clinical trials to show that they are safe to use and, in some cases, show some signs of being effective.

This team developed a way to isolate some heart-specific stem cells that are found in adult heart muscle. They use clumps of cells called Cardiospheres to reduce scarring caused by heart attacks. Initially they used cells obtained from the patients own heart but they later developed methods to obtain the cells they need from donor organs, which allows the procedure to become an off-the-shelf-therapy, meaning it can be available when and where the patient needs it rather than having to create it new each time. The company, working with the Cedars-Sinai team, received FDA approval to begin a clinical trial in June 2012.

Read the rest here:
Heart Disease Fact Sheet | California's Stem Cell Agency

CardioCel has been initially well received with surgeons in Australia and overseas. Photo: Geoff Fisher

For 10 years researchers at Admedus worked day and night trying to work out how to improve soft tissue repair in the human body.

And with the vital help of CSIRO they have been to develop CardioCel, a life-saving heart patch for the repair and reconstruction of cardiovascular defects.

According to the Children's Heart Foundation, congenital heart disease occurs in one out of 100 births and in at least half of those cases surgery is required and a patch is needed. They state it is the leading cause of birth defect related deaths.

Research undertaken with CSIRO investigated new, potentially ground-breaking applications for CardioCel. The research focused on using stem cells. It found the heart patch has the potential to deliver stem cells and help tissue heal better than other existing products, when used for cardiac repair.

Advertisement

Derived from animal tissue, the CardioCel patch is engineered over 14 days.

"The first unique feature of this product is that it doesn't calcify in young patients," Professor Leon Neethling, Admedus technical director and heart researcher says.

The flexible patch works like human tissue to cover holes in the heart thereby eliminating the need for repeat surgery.

"In the cardiac repair field it has long been recognised that strong, flexible, biocompatible and calcification-resistant tissue scaffolds would be ideal tissues for repair of heart defects," Admedus' chief operating officer Dr Julian Chick, says.

The rest is here:
Local innovation repairs holes in the heart

Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center
How can PRP and stem cell therapy help you heal? Orlando Orthopaedic Center #39;s Dr. Matthew R. Willey explains. For more visit http://www.OrlandoOrtho.com.

By: OrlandoOrtho

Read more:
Can PRP and Stem Cell Therapy Help You? | Orlando Orthopaedic Center - Video

$1 M gift from Mr. J. Sebastian van Berkom launches translational research into neurological disease

This news release is available in French.

A patient's very own skin cells may hold the key to new treatments and even cures for devastating neurological diseases. A generous $1 million donation from Mr. J. Sebastian van Berkom, and critical partnerships with Brain Canada, Laval University, Marigold Foundation and the FRQS-Rseau Parkinson Quebec are driving an innovative, iPSC (induced pluripotent stem cell) research platform that will transform research into Parkinson's and other neurological diseases.

Millions of Canadians are affected by diseases of the brain such as ALS, Parkinson's and brain tumours, for which there are limited treatments and no cures. By 2020, neurological conditions will become the leading cause of death and disability. "Everyone's lives are touched in some way by neurological disease, says Mr. van Berkom, President of Van Berkom and Associates Inc." In creating The van Berkom Parkinson's Disease Open-Access Fund, I hope to change lives and support new research that will lead to new treatments and one day cures. The iPSC platform is a new paradigm for neuroscience research and as one of the world's great neuroscience centres, The Neuro is the place to drive it forward."

"This is the ultimate bench to bedside paradigm, from patient to the bench, back to the patient," says Dr. Guy Rouleau, Director of The Neuro. "With a unique interface between fundamental and clinical research, The Neuro is uniquely positioned to be a central hub in the iPSC platform. Partnering with Mr. Van Berkom, a generous and visionary philanthropist, propels The Neuro toward the goal of significantly deepening insight into disease mechanisms with unprecedented efficiency."

Patients' skin cells will be reprogrammed into induced pluripotent stem cells (iPSCs) at Laval University, under the leadership of Dr Jack Puymirat, and then differentiated at The Neuro into disease relevant cells for research. For example, in the case of Parkinson's this could be dopamine neurons. The cells can also be genome-edited, a state-of-the-art technique that can introduce or correct disease associated mutations - creating the most accurate disease models. These iPSCs will be made widely and openly available to researchers across Quebec for neuroscience research. This open-access approach exponentially increases the likelihood of breakthroughs in neurological disease.

"The unique and exciting aspect of this platform is that we are creating the most specific cells for studying disease using the patient's own tissue, which has distinct advantages over using generic cells or animal models," says Dr. Edward Fon, neurologist and co-Director of the Quebec iPSC platform. "Disease models using human samples are increasingly shown to be far more efficacious in trials, as they much more accurately mimic the disease condition. In the iPSC platform, not only can specific mutations be introduced but, cells are from patients' whose specific clinical history and genetic profile are known, a first step on the road toward neurological personalized medicine. The Neuro has access to a large and well-characterized patient population, who can help create a rich clinically-and genetically-derived registry and biobank. The initial targets in the platform will be ALS and Parkinson's disease (PD), using dopamine neurons for PD and both motor neurons and astrocytes for ALS."

The Quebec iPSC core facility is a provincial core headed by Drs. Fon and Puymirat. Reprogrammed cells at Laval University will be created from different sources such as skin biopsies, blood or urine. The Neuro's component of the platform will consist of two core facilities. The iPSC neuronal differentiation core - which differentiate iPSCs into functional neurons, headed by Dr. Eric Shoubridge, and the iPSC genome-editing core providing unprecedented ability to study the influence of disease mutations, headed by Dr. Peter McPherson.

###

The Montreal Neurological Institute and Hospital

Go here to see the original:
Using patients' own cells to accelerate research into neurological disease

(SACRAMENTO, Calif.) - The state stem cell agency, California Institute for Regenerative Medicine (CIRM),awarded a pair of grants totaling more than $7 million to UC Davis School of Medicine researchers who are working to develop stem cell therapies for spina bifida and chronic diabetic wounds. The funding is part of what the agency considers "the most promising" research leading up to human clinical trials using stem cells to treat disease and injury. Diana Farmer, professor and chair of surgery at UC Davis Medical Center, is developing a placental stem cell therapy for spina bifida, the common and devastating birth defect that causes lifelong paralysis as well as bladder and bowel incontinence. She and her team are working on a unique treatment that can be applied in utero - before a baby is born -- in order to reverse spinal cord damage. Roslyn Rivkah Isseroff, a UC Davis professor of dermatology, and Jan Nolta, professor of internal medicine and director of the university's Stem Cell Program, are developing a wound dressing containing stem cells that could be applied to chronic wounds and be a catalyst for rapid healing. This is Isseroff's second CIRM grant, and it will help move her research closer to having a product approved by the U.S. Food and Drug Administration that specifically targets diabetic foot ulcers, a condition affecting more than 6 million people in the country. The CIRM board, which met in Berkeley today, has high hopes for these types of research that the agency funded in this latest round of stem cell grants. "This investment will let us further test the early promise shown by these projects," said Jonathan Thomas, chair of CIRM's governing board. "Preclinical work is vital in examining the feasibility, potential effectiveness and safety of a therapy before we try it on people. These projects all showed compelling evidence that they could be tremendously beneficial to patients. We want to help them build on that earlier research and move the projects to the next level." The CIRM grants are designed to enable the UC Davis research teams to transition from preclinical research to preclinical development over the next 30 months to be able to meet the FDA's rigorous safety and efficacy standards for Investigative New Drugs. As the former surgeon-in-chief at UCSF Benioff Children's Hospital, Farmer helped pioneer fetal surgery techniques for treating spina bifida before birth. The condition, also known as myelomeningocele, is one of the most common and devastating birth defects worldwide, causing lifelong paralysis as well as bowel and bladder incontinence in newborns. Farmer has been investigating different stem cell types and the best way to deliver stem cell-based treatments in the womb for the past six years. She and her research colleagues recently discovered a placental therapy using stem cells that cures spina bifida in animal models. That discovery requires additional testing and FDA approval before the therapy can be used in humans. With the CIRM funding, Farmer and her team plan to optimize their stem cell product, validate its effectiveness, determine the optimal dose and confirm its preliminary safety in preparation for human clinical trials. Isseroff, who also serves as chief of dermatology and director of wound healing services for the VA Northern California Health Care System, has long been frustrated by the challenges of treating the chronic, non-healing wounds of diabetics. In 2010, she and Nolta received a CIRM grant to begin developing a bioengineered product for treating chronic diabetic wounds. Foot ulcers, in particular, affect about 25 percent of all diabetic patients and are responsible for most lower-limb amputations. Isseroff and her research team created a treatment using stem cells derived from bone marrow (mesenchymal stem cells) along with a FDA-approved scaffold to help regenerate dermal tissue and restart the healing process. Their studies found the technique to be highly effective for healing wounds in animal models. With this latest CIRM grant, Isseroff's team will refine their therapeutic technique by determining the safest dosage for regenerating tissue and testing their product in skin-wound models that closely resemble those in diabetic humans. Nolta also plans to create a Master Cell Bank of pure and effective human mesenchymal stem cells, and establish standard operating procedures for use in diabetic wound repair. The results of their efforts will enable UC Davis to move closer to FDA approval for human clinical trials in the next two and a half years. "These amazing research efforts are giant steps forward in turning stem cells into cures," said Nolta, who also directs the UC Davis Institute for Regenerative Cures in Sacramento. "This preclinical research is the most crucial, and often the toughest, stage before we move scientific discoveries from the laboratory bench to the patient's bedside. We are now poised as never before to make a big difference in the lives of people with spina bifida and non-healing diabetic wounds." For more information, visit UC Davis School of Medicine at http://medschool.ucdavis.edu.

More:
Stem Cell Grants for Spina Bifida and Diabetic Wound Treatments

Tampa, FL. (PRWEB) March 26, 2015

This month, the Lung Institute has started treating people suffering from chronic lung diseases with stem cells extracted from their bone marrow. This treatment protocol is added to the two other treatment options offered by the Lung Institute: venous (blood-derived) and adipose (fat-derived) stem cell therapy.

The bone marrow and adipose treatments offer the highest concentration of stem cells and allow for the cells to be reintroduced directly into the lungs through a nebulizer. Given this added benefit, most patients in the past opted to receive the adipose treatment over venous. However, many patients have other medical conditions that preclude them from choosing the adipose treatment. Since the number of stem cells harvested from a bone marrow procedure matches that of the adipose procedure, patients that have previously only qualified for the venous procedure are now eligible for a treatment option that produces the highest chance of success.

Patients are often surprised by the simplicity of these minimally invasive procedures, but with cutting-edge technology and the patient-centric clinical team at the Lung Institute, patients can rest assured that they are in good hands. Throughout the entire treatment process, patients have the opportunity to get any questions immediately answered by our knowledgeable medical staff. The Lung Institute clinical team remains in contact with patients after treatment and works together with the patients physician and pulmonologist to create a strong support system for the patient.

About the Lung Institute At the Lung Institute, we are changing the lives of hundreds of people across the nation through the innovative technology of regenerative medicine. We are committed to providing patients a more effective way to address pulmonary conditions and improve their quality of life. Our physicians, through their designated practices, have gained worldwide recognition for the successful application of revolutionary minimally invasive stem cell therapies. With over a century of combined medical experience, our doctors have established a patient experience designed with the highest concern for patient safety and quality of care. For more information, visit our website at LungInstitute.com, like us on Facebook, follow us on Twitter or call us today at (855) 313-1149.

See original here:
Lung Institute Announces New Treatment with Bone Marrow

My bone marrow began sending me messages long before I Learned to listen..I was exhausted, pale, drained, and tired all of the time. I eventually landed myself in the emergency room, and was handed a full membership to the cancer club. I was diagnosed with multiple myeloma, an incurable blood cancer.

My bone marrow began sending me messages long before I Learned to listen..I was exhausted, pale, drained, and tired all of the time. I eventually landed myself in the emergency room, and was handed a full membership to the cancer club. I was diagnosed with multiple myeloma, an incurable blood cancer.

That was June 23, 2009.

As it turned out I was very fortunate. I beat the statistical odds and circumstances were in my favour. After four months of chemo and steroids, I was able to use my own stem cells in what is called an autologous stell cell transplant.

My stem cell transplant was a journey to my very core. It's like witnessing a rebirth. It's awe-inspiring and essential. Visualizing those 'yellow' cells stream their way back into my bone marrow opened my eyes to the singular power stem cells bring into our world.

But I was also reminded of Michael Pinto the undertaker in Bombay.

'Grave Problems Resurrected here'

That's so not gonna happen. Not on my resurrection.

My passage through illness taught me that the knowledge of the curative properties of stem cells needs to be shared to offer hope of renewed life. If you knew what medical science can do with stem cells, and if you saw what I did in the labs, through microscropes, you too would feel like using both hands to scoop those secrets out into the world.

Occasionally I gloss over my past cancer club membership--my treatment, my illnessbut then I am remember what a profound reboot my body has gone through, and I remember why. It's true that the deepest crises are moments of great opportunity; an event that shocks you into seeing with your heart. It is a place that combines survival with celebration.

Read more here:
My message in a bottle, writes Lisa Ray

Stem Cell Therapy - Lilli Donovan
Created using PowToon -- Free sign up at http://www.powtoon.com/join -- Create animated videos and animated presentations for free. PowToon is a free tool that allows you to develop cool...

By: Lilli Donovan

View post:
Stem Cell Therapy - Lilli Donovan - Video

SuperCells at Centre for Life
Exhibition at Centre for Life, Newcastle. Exhibition presented by the Stem Cell Network and produced by the Sherbrooke Museum of Nature and Science (Quebec, Canada); in partnership with the...

By: Cell Therapy Catapult

Read the original post:
SuperCells at Centre for Life - Video

Scientists at the University of Cambridge have successfully created 'mini-lungs' using stem cells derived from skin cells of patients with cystic fibrosis, and have shown that these can be used to test potential new drugs for this debilitating lung disease.

The research is one of a number of studies that have used stem cells - the body's master cells - to grow 'organoids', 3D clusters of cells that mimic the behaviour and function of specific organs within the body. Other recent examples have been 'mini-brains' to study Alzheimer's disease and 'mini-livers' to model liver disease. Scientists use the technique to model how diseases occur and to screen for potential drugs; they are an alternative to the use of animals in research.

Cystic fibrosis is a monogenic condition - in other words, it is caused by a single genetic mutation in patients, though in some cases the mutation responsible may differ between patients. One of the main features of cystic fibrosis is the lungs become overwhelmed with thickened mucus causing difficulty breathing and increasing the incidence of respiratory infection. Although patients have a shorter than average lifespan, advances in treatment mean the outlook has improved significantly in recent years.

Researchers at the Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute used skin cells from patients with the most common form of cystic fibrosis caused by a mutation in the CFTR gene referred to as the delta-F508 mutation. Approximately three in four cystic fibrosis patients in the UK have this particular mutation. They then reprogrammed the skin cells to an induced pluripotent state, the state at which the cells can develop into any type of cell within the body.

Using these cells - known as induced pluripotent stem cells, or iPS cells - the researchers were able to recreate embryonic lung development in the lab by activating a process known as gastrulation, in which the cells form distinct layers including the endoderm and then the foregut, from which the lung 'grows', and then pushed these cells further to develop into distal airway tissue. The distal airway is the part of the lung responsible for gas exchange and is often implicated in disease, such as cystic fibrosis, some forms of lung cancer and emphysema.

The results of the study are published in the journal Stem Cells and Development.

"In a sense, what we've created are 'mini-lungs'," explains Dr Nick Hannan, who led the study. "While they only represent the distal part of lung tissue, they are grown from human cells and so can be more reliable than using traditional animal models, such as mice. We can use them to learn more about key aspects of serious diseases - in our case, cystic fibrosis."

The genetic mutation delta-F508 causes the CFTR protein found in distal airway tissue to misfold and malfunction, meaning it is not appropriately expressed on the surface of the cell, where its purpose is to facilitate the movement of chloride in and out of the cells. This in turn reduces the movement of water to the inside of the lung; as a consequence, the mucus becomes particular thick and prone to bacterial infection, which over time leads to scarring - the 'fibrosis' in the disease's name.

Using a fluorescent dye that is sensitive to the presence of chloride, the researchers were able to see whether the 'mini-lungs' were functioning correctly. If they were, they would allow passage of the chloride and hence changes in fluorescence; malfunctioning cells from cystic fibrosis patients would not allow such passage and the fluorescence would not change. This technique allowed the researchers to show that the 'mini-lungs' could be used in principle to test potential new drugs: when a small molecule currently the subject of clinical trials was added to the cystic fibrosis 'mini lungs', the fluorescence changed - a sign that the cells were now functioning when compared to the same cells not treated with the small molecule.

"We're confident this process could be scaled up to enable us to screen tens of thousands of compounds and develop mini-lungs with other diseases such as lung cancer and idiopathic pulmonary fibrosis," adds Dr Hannan. "This is far more practical, should provide more reliable data and is also more ethical than using large numbers of mice for such research."

Read more:
Scientists grow 'mini-lungs' to aid the study of cystic fibrosis

Stem cell therapy and me1
Walk without support.

By: drabhijitshendeji

Go here to see the original:
Stem cell therapy and me1 - Video

Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM
http://r3stemcell.com/stem-cell-treatments/amniotic-derived-stem-cell-injections/ Amniotic derived stem cell therapy has become exceptionally popular due to the benefits that are being seen....

By: R3 Stem Cell

Read more:
Amniotic Stem Cell Therapy Discussed by R3 (844) GET-STEM - Video

The Alpha Clinic for Cell Therapy and Innovation | City of Hope
A new grant to City of Hope from the California Institute for Regenerative Medicine (CIRM) will make it possible for novel stem cell based therapies developed here at City of Hope to...

By: City of Hope

See original here:
The Alpha Clinic for Cell Therapy and Innovation | City of Hope - Video

Boston, MA (PRWEB) March 18, 2015

In the vast flow of new scientific research, discoveries, and information, it is not uncommon for important scientific advances to go unappreciated, or even just unnoticed, for surprisingly long periods of time. The Boston stem cell medicine technology start-up company, Asymmetrex is working to make sure that its growing portfolio of adult tissue stem cell technology patents obtains wide notice, appreciation, and investment.

In late 2014, the company started a digital media campaign to achieve greater visibility for its patented technologies that address the major barriers to greater progress in stem cell medicine. These include technologies for identifying, counting, and mass-producing adult tissue stem cells. The two presentations scheduled for the 5th World Congress on Cell and Stem Cell Research in Chicago continue Asymmetrexs efforts to better inform medical, research, and industrial communities focused on advancing stem cell medicine of the companys vision for implementation of its unique technologies.

Asymmetrex holds patents for the only method described for routine production of natural human tissue stem cells that retain their normal function. The company also holds patents for biomarkers that can be used to count tissue stem cells for the first time. The companys most recently developed technology was invented with computer-simulation leader, AlphaSTAR Corporation. In partnership, the two companies created a first-of-its-kind method for monitoring adult tissue stem cell number and function for any human tissue that can be cultured. This advance is the basis for the two companies AlphaSTEM technology for detecting adult tissue stem cell-toxic drug candidates before conventional preclinical testing in animals or clinical trials. Asymmetrex and AlphaSTAR plan to market the new technology to pharmaceutical companies. The implementation of AlphaSTEM technology would accelerate drug development and reduce adverse drug events for volunteers and patients. At full capacity use, AlphaSTEM could reduce U.S. drug development costs by $4-5 billion each year.

About Asymmetrex (http://asymmetrex.com/)

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrexs founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The companys patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrexs focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.

More here:
Boston Stem Cell Biotech Start-up Asymmetrex Will Present Essential Technologies for Stem Cell Medical Engineering at ...

Stem Cell Therapy- Sci Video2
Created using PowToon -- Free sign up at http://www.powtoon.com/join -- Create animated videos and animated presentations for free. PowToon is a free tool that allows you to develop cool...

By: Georgia McDonald

Read the rest here:
Stem Cell Therapy- Sci Video2 - Video

Orthopedic Stem Cell Therapy - Queens, New York
Benjamin Bieber MD of #CrossBayPMR in Howard Beach, New York has had great success with #stemcell therapy using your own fat cells. Avoid invasive #jointreplacement surgery and get back to...

By: Cross Bay Physical Medicine and Rehabilitation, P.C.

Read this article:
Orthopedic Stem Cell Therapy - Queens, New York - Video

BOSTON (TheStreet) --A question about Neuralstem (CUR - Get Report) and its stem-cell therapy for ALS kicks off this week's Biotech Stock Mailbag.

Steve writes, "If 47% of the people responded well and their progression of the disease slowed considerably, then I see this as a huge success for a disease with no cure. I don't have ALS or know anyone that does, but if I had it, I would immediately want the treatment knowing that there is a 47% chance that I will respond positively to it and it would DRASTICALLY slow the progression of the disease. Wouldn't you agree, or am I missing the point somewhere?"

Eight of the 15 (53%) ALS patients enrolled in the study saw their ALSFRS scores fall from an average of 40 to 14 over nine months. This is a rapid decline in muscle function and suggests NSI-566 accelerates the progression of ALS.

If you believe 47% of patients in the Neuralstem study benefit from NSI-566, you can't ignore the 53% of patients who fare far worse and may actually be harmed by the stem cell therapy.

Link:
Biotech Stock Mailbag: Neuralstem, Genfit, Intercept, Amarin